Plain-English translation of NCT07470853 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This trial is testing a new cancer medication called HWK-016, which is designed to attack cancer cells by targeting a protein called MUC16 that appears on certain tumors. Researchers are conducting this early-stage study to find the right dose and to see how well and how safely the medication works in people with advanced ovarian or endometrial cancer. Some participants may also receive this medication combined with another drug called .
Many people with advanced ovarian and endometrial cancers need new treatment options, especially when standard therapies stop working or cause too many side effects. This medication represents a new approach to fighting these cancers by using an antibody to deliver cancer-fighting drugs directly to tumor cells.
You likely qualify if…
You likely don't qualify if…
You would visit a clinic every 3 weeks to receive an intravenous infusion of the medication; the study starts with smaller doses that gradually increase to find the safest and most effective amount. Throughout the trial, you'll have regular blood tests, scans, and check-ins with your medical team to monitor how you're responding and to watch for any side effects. The study has multiple stages, beginning with dose-finding and moving into larger groups of participants at the recommended dose, with the goal of enrolling around 265 people total.
AI-generated summary from trial data · Aug 24, 2026 · Not medical advice
United States